WO2002011762A3 - Methods and compositions for modulating tumor growth - Google Patents
Methods and compositions for modulating tumor growth Download PDFInfo
- Publication number
- WO2002011762A3 WO2002011762A3 PCT/CA2001/001111 CA0101111W WO0211762A3 WO 2002011762 A3 WO2002011762 A3 WO 2002011762A3 CA 0101111 W CA0101111 W CA 0101111W WO 0211762 A3 WO0211762 A3 WO 0211762A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- tumor growth
- compositions
- modulating tumor
- administered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001278338A AU2001278338A1 (en) | 2000-08-03 | 2001-07-30 | Methods and compositions for modulating tumor growth |
CA2417874A CA2417874C (en) | 2000-08-03 | 2001-07-30 | Use of ox-2 inhibitors for the treatment of cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22272500P | 2000-08-03 | 2000-08-03 | |
US60/222,725 | 2000-08-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002011762A2 WO2002011762A2 (en) | 2002-02-14 |
WO2002011762A3 true WO2002011762A3 (en) | 2003-03-13 |
Family
ID=22833418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2001/001111 WO2002011762A2 (en) | 2000-08-03 | 2001-07-30 | Methods and compositions for modulating tumor growth |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2001278338A1 (en) |
CA (1) | CA2417874C (en) |
WO (1) | WO2002011762A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60135573D1 (en) | 2000-11-22 | 2008-10-09 | Trillium Therapeutics Inc | SHORTEN CD200 |
AU2002246632B2 (en) | 2000-12-08 | 2007-04-05 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line and its use for producing an antibody |
AU2004217434B2 (en) * | 2000-12-08 | 2010-08-26 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US9249229B2 (en) | 2000-12-08 | 2016-02-02 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US20040198661A1 (en) * | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
NZ553470A (en) * | 2002-03-15 | 2008-10-31 | Schering Corp | Methods of modulating CD200 receptors |
MXPA05006978A (en) * | 2002-12-27 | 2005-08-16 | Schering Corp | Methods of inducing and maintaining immune tolerance. |
AU2012211347B9 (en) * | 2004-07-20 | 2015-06-18 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
PL2463305T3 (en) | 2006-01-12 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Antibodies to OX-2/CD200 and uses thereof |
BRPI0814645A2 (en) | 2007-07-25 | 2015-01-27 | Alexion Pharma Inc | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE. |
CN102906115A (en) | 2010-01-11 | 2013-01-30 | 阿雷克森制药公司 | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
AU2011215750A1 (en) | 2010-02-11 | 2012-08-23 | Alexion Pharmaceuticals, Inc. | Therapeutic methods using an ti-CD200 antibodies |
EP3626739A1 (en) | 2011-06-24 | 2020-03-25 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
RU2769282C2 (en) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Anti-pd-l1 and il-2 cytokines |
US11761963B2 (en) | 2017-09-27 | 2023-09-19 | Alexion Pharmaceuticals, Inc. | Biomarker signature for predicting tumor response to anti-CD200 therapy |
US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024565A1 (en) * | 1997-11-07 | 1999-05-20 | Transplantation Technologies Inc. | Methods and compositions for immunomodulation |
-
2001
- 2001-07-30 WO PCT/CA2001/001111 patent/WO2002011762A2/en active Application Filing
- 2001-07-30 AU AU2001278338A patent/AU2001278338A1/en not_active Abandoned
- 2001-07-30 CA CA2417874A patent/CA2417874C/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024565A1 (en) * | 1997-11-07 | 1999-05-20 | Transplantation Technologies Inc. | Methods and compositions for immunomodulation |
Non-Patent Citations (2)
Title |
---|
J. NI ET AL.: "An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant which prolongs allograft survival.", THE FASEB JOURNAL, vol. 13, no. 5, 15 March 1999 (1999-03-15), Bethesda, MD, USA, pages A983, XP000960581 * |
R. RAGHEB ET AL.: "Preparation and functional properties of monoclonal antibodies to human, mouse and rat OX-2.", IMMUNOLOGY LETTERS, vol. 68, no. 2-3, 1 June 1999 (1999-06-01), Amsterdam, The Netherlands, pages 311 - 315, XP000960642 * |
Also Published As
Publication number | Publication date |
---|---|
CA2417874A1 (en) | 2002-02-14 |
CA2417874C (en) | 2012-10-02 |
AU2001278338A1 (en) | 2002-02-18 |
WO2002011762A2 (en) | 2002-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002011762A3 (en) | Methods and compositions for modulating tumor growth | |
WO2001064246A3 (en) | Farnesyl protein transferase inhibitor combinations with an her2 antibody | |
WO2001092581A8 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
WO2005044976A3 (en) | Oligomeric compounds for use in gene modulation | |
WO2003014303A3 (en) | Molecular interactions in cells | |
AU2002236300A1 (en) | Novel protein, gene encoding the same and method of using the same | |
AU2003297318A1 (en) | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. | |
WO2001075178A3 (en) | Methods for identifying peptide aptamers capable of altering a cell phenotype | |
WO2003045309A3 (en) | Peptides, peptide compositions,and methods of use in binding p 185 | |
WO2002044376A8 (en) | Modulation of gene expression using insulator binding proteins | |
AU4100199A (en) | Compositions and methods for enhancing protein anabolism and detoxification | |
HK1049185A1 (en) | Modified fluorescent proteins | |
EP1351573A4 (en) | Methods for modulating tumor growth and metastasis | |
AU2001263269A1 (en) | Long wavelength engineered fluorescent proteins | |
AU2002311859A1 (en) | Compositions and methods for treating colorectal polyps and cancer | |
WO2002039885A3 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
WO2001053524A3 (en) | Cancer associated genes and their products | |
WO2003000901A3 (en) | Nucleic acids encoding protein kinases | |
AU2001291308A1 (en) | Methods and compositions for treating nail fungus | |
WO2003030719A3 (en) | Methods and kits for use in selecting approaches to treating cancer | |
WO2002026960A3 (en) | Modulation of gene expression using localization domains | |
WO1999047709A3 (en) | Methods for identifying anti-cancer agents | |
EP1273296A3 (en) | Combination chemotherapy | |
AU2002228940A1 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
WO1999065450A3 (en) | Immunosuppressive agents that inhibit calcineurin function and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2417874 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |